Navigation Links
Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology
Date:10/30/2007

FREISING-WEIHENSTEPHAN, Germany, October 30 /PRNewswire/ -- Pieris AG (Munich, Germany) and Pepscan Therapeutics (Lelystad, Netherlands) today announced the commencement of a research collaboration aimed at identifying Anticalins(R) specific for G-Protein Coupled Receptors (GPCRs) and their development as therapeutic candidates.

Pieris has pioneered Anticalins(R) as next generation targeted therapeutics with clear advantages over monoclonal antibodies, while Pepscan has developed CLIPS(TM) technology to yield immunogens targeting functional epitopes on proteins. Through this newly announced collaboration, the companies aim to combine and apply their respective technologies to the discovery and development of novel Anticalins(R) able to modulate GPCR function in disease.

GPCRs form one of the most important classes of drug targets, yet for many of these receptors, no pharmacologically active small molecule drugs have been identified. Biotherapeutics provide an intriguing alternative if they can be selectively targeted to functional epitopes, yet monoclonal antibodies modulating GPCR action have to date proven technically challenging. Pepscan's CLIPS(TM) technology has the distinct advantage of selectively identifying functional mimics of the extracellular portions of GPCRs which are fundamental in biology. Such mimics will be used by Pieris to select Anticalins(R) with disease modifying potential.

"Pieris has successfully isolated and characterised high potency Anticalins(R) against structurally diverse functional epitopes on a wide range of medically relevant proteins", said Dr Andreas Hohlbaum, Director of Science and Preclinical Development at Pieris. "Incorporating Pepscan's CLIPS(TM) technology into our selection and screening process now allows us to discover Anticalins(R) with high affinity and selectivity for specific GPCRs".

Dr Rob Meloen, Chief Scientific Officer of Pepscan Therapeutics commented: "Functional binding proteins directed against GPCRs are in great demand as disease-targeting agents. This collaboration allows Pepscan to apply its protein mimicry technology to GPCRs for the identification of Anticalins(R) with therapeutic potential".

Notes to editors

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins(R), a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

About Anticalin(R) Technology

Anticalins are engineered by Pieris from the scaffold of human lipocalins, a family of natural ligand binding proteins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Being human in origin, Anticalins are predicted to have minimal immunogenicity in man. Where Anticalins benefit compared to conventional antibodies is in their small size (20 kDa), their robust physicochemical properties and their simple composition that together allow highly soluble, predictably stable products to be manufactured from bacteria. Anticalins are amenable to further engineering to balance their favorable tissue penetration with adjustable serum clearance. Moreover, Anticalins have been developed as Duocalins(R), whose dual targeting format allows multiple targets to be bound and modulated through a single molecule.

Further information is available at http://www.pieris-ag.com

Anticalin(R) is a registered trademark of Pieris AG.

About Pepscan Therapeutics

Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccines of which the most advanced is in Phase II clinical testing. Pepscan's proprietary CLIPS(TM) technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs.

About CLIPS(TM) Technology

Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS(TM)) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains that serve as superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g GPCRs, ion channels, patented proteins).

Further information is available at http://www.pepscan.com

For further information, please contact

Pieris AG

Dr Birgit Zech

Senior Manager Business Development

Phone +49(0)8161-1411-400

Pepscan Therapeutics

Peter van Dijken

Chief Commercial Officer

Phone +31(0)320-237-200


'/>"/>
SOURCE Pieris AG
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
2. Now you can identify Sperm and Egg donors
3. Identifying Predictors Of Anthrax
4. Identifying The Risks Of Developing Schizophrenia
5. Researchers identify the early makers of Neonatal Sepsis
6. Researchers Identify Gene Connected To Bipolar Disorder
7. Blood test may identify ovarian cancer
8. Identifying bacteria made amiable
9. Latest device for identifying Melanomas
10. Identifying brain lesions with impaired consciousness
11. Identifying Virus Found To Be Essential for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients ... and weekends so that visits to the dentist fit into their patients’ busy ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for fiscal ... four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as a ... all charities reviewed by Charity Navigator and earns ANRF a spot on their “ ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection ... denied entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger ... six years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Breast Cancer Conference from Sept. 18 to 20. , The two-day conference is ... subtype with the goal of improving patients’ lives and eliminating racial breast cancer-related ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology: